Examples of using More subsets in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
The European Medicines Agency has deferred the obligation to submit the results of studies with KRYSTEXXA in one or more subset of the paediatric population in the treatment and/or prevention of hyperuricaemia related to Tumour Lysis Syndrome see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Episalvan in one or more subsets of the paediatric population for the treatment of skin injuries.
The European Medicines Agency has deferred the obligation to submit the results of studies with KANUMA in one or more subsets of the paediatric population in LAL deficiency see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with belatacept in one or more subsets of the paediatric population in renal transplantation see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Elonva in one or more subsets of the paediatric population in hypogonadotrophic hypogonadism see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of clinical studies with Truberzi in one or more subsets of the paediatric population in IBS-D see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with canagliflozin in one or more subsets of the paediatric population in type 2 diabetes see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies withOptaflu in one or more subsets of the paediatric population in the prevention of influenza see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Cotellic in one or more subsets of the paediatric population in malignant solid tumours see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Feraccru in one or more subsets of the paediatric population in iron deficient anaemia see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Omidria in one or more subsets of the paediatric population in lens therapeutic procedures see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with INCIVO in one or more subsets of the paediatric population in chronic hepatitis C see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with MIRAPEXIN in one or more subsets of the paediatric population in Restless Legs Syndrome see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with vandetanib in one or more subsets of the paediatric population in hereditary medullary thyroid carcinoma see 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies in one or more subsets of the paediatric population in the treatment of heart failure see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis(see section 4.2 for information on paediatric use).
The European Medicines Agency has deferred the obligation to submit the results of studies with ustekinumab in one or more subsets of the paediatric population in Crohn's Disease see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with ISENTRESS in one or more subsets of the paediatric population in Human Immunodeficiency virus infection see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with cobicistat in one or more subsets of the paediatric population in treatment of HIV-1 infection see section 4.2 for information on paediatric use.
The European Medicines Agency has deferred the obligation to submit the results of studies with Januvia in one or more subsets of the paediatric population in type 2 diabetes mellitus see section 4.2 for information on paediatric use.